Skip to main content
. 2021 May 4;12:668002. doi: 10.3389/fimmu.2021.668002

Figure 2.

Figure 2

Melatonin protects against chronic LPS-induced mouse lung destruction by the targeting MT1/MT2 receptor. (A–D) Melatonin inhibited BALT formation and bronchial thickening as well as alveolar enlargement compared with LPS treatment. Mice receiving luzindole (MT1/MT2 inhibitor) intraperitoneal injection showed diminished protective effects of melatonin in their lungs. N = 5–7 in each group. (E, F) Micro-CT indicated that mice treated with melatonin had less destruction in their lungs under chronic LPS exposure. However, luzindole (MT1/MT2 inhibitor) increased the amount of destruction in the lungs even when mice were treated with melatonin. N = 5–7 in each group. (G–J) Melatonin preserved the number of cilia and normal morphology of mitochondrial autophagosomes in mouse bronchial epithelial cells under LPS exposure. However, luzindole (MT1/MT2 inhibitor) intraperitoneal injection reduced the cilia and increased the percentage of abnormal mitochondria and mitochondrial autophagosomes, although mice received melatonin orally daily. N = 4 in each group. The green arrow shows cilia, the yellow arrow shows mitochondrial autophagosomes, the red arrow shows autophagosomes, and the black arrow shows lysosomes. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.